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Abstract
The incidence and mortality of breast cancer are rising in the whole world in 
the past few decades, adding up to a total of around two million new cases and 
620,000 deaths in 2018. Unlike what occurs in developed countries, most of the 
cases diagnosed in the developing world are already in advanced stages and also 
in women younger than 50 years old. As most screening programs suggest annual 
mammograms starting at the age of 50, we can infer that a considerable portion of 
the new breast cancer cases is missed with this strategy. Here, we will propose the 
adoption of an alternative hierarchical patient flow, with the creation of a diagnostic 
fast track with referral to timely treatment, promoting better resources reallocation 
favoring the least advantaged strata of the population, which is not only ethically 
acceptable but also a way of promoting social justice.
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1. Introduction
According to data from the World Health Organization (WHO), the number of 
deaths due to cancer will increase up to 45% between 2008 and 2030 and 70% of 
those deaths will occur in developing countries [1]. To try and change this scenario, 
the WHO recommends the implementation of cancer control programs that must 
include cost-effective measures on healthy life style, vaccination programs and 
screening programs [2]. A screening program consists in a set of coordinated 
actions with the objective of reducing cancer mortality through early stage diag-
nosis in an asymptomatic population, with adequate referral to diagnostic and 
treatment facilities. These programs have four main components: the definition and 
recruitment of the target population, adequate offer of diagnostic tests with quality 
assurance, guaranteed offer of follow up exams and biopsies to confirm findings 
from the initial diagnostic tests, and referral to treatment facilities and timely 
navigation through the health system [3]. Although screening programs present 
the potential benefit of reducing mortality, they are not risk-free. The main risks of 
such a program are the false-positive and false-negative results, and also the occur-
rence of over diagnosis. All these can lead to clinical and psychological repercus-
sions and, also, to the increase in the health care system expenditure. To address this 
issue, the Public Health Agency of Canada performed a study to estimate the harms 
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of the local breast cancer-screening program in 7 years, according to age, and the 
main results can be seen in Table 1 [4].
In this text, we will use Brazil as a model to discuss screening programs in the 
developing countries. In the Brazilian setting, breast cancer is the most frequent type 
of cancer, responsible for 16,724 deaths in 2017 and with an estimate of 66,280 new 
cases in 2020 [5]. This scenario, however, has some peculiarities when compared 
to developed countries in the North America or Europe; 41.1% of all cases in Brazil 
happen in women younger than 50 years old and the majority of the operable cases is 
diagnosed in locally advanced stages, being 53.3% of the cases in stage II and 23.2% in 
stage III [6]. These characteristics are not typical of a country with a well-established 
breast cancer-screening program. The strategy adopted in Brazil states that women 
over 50 should get a mammogram every two years between 50 and 69 years old [7]. 
However, due to the early age of diagnosis that we observe in this developing country, 
we can argue that more than 40% of the diagnosed women are not eligible to the 
screening program in the first place. Moreover, the late presentation at diagnosis raises 
the hypothesis that the current screening program is not effective or that the patients 
do not have proper access to it. Added to that, the mortality due to breast cancer 
in Brazil has been increasing in the last decades [8]. All these issues taken together 
generate an ethical dilemma to be explored, once the investment of public resources in 
an ineffective program impacts negatively the whole society. This way, more effective 
resources reallocation strategies should be implemented to address this dilemma.
In this chapter we will discuss the breast cancer screening programs in 
developing countries and the main evidence regarding the barriers in the access 
to the healthcare system. Beyond that, we will address the main ethical ques-
tions related to breast cancer screening from the Rawls’s distributive justice [9] 
perspective, from the utilitarianism concepts [10, 11] and from the principles 
of autonomy and non-maleficence. Lastly, we will propose the support to an 
alternative approach to breast cancer in developing countries, maximizing the 
cost–benefit ratio in the use of public resources.
Age Range 40–49 years 
old
50 to 59 years 
old
60 to 69 years 
old
70 to 74 years 
old
Screening strategy Annual 
mammogram
Mammogram 
every two years
Mammogram 
every two years
Mammogram 
every two years
Women that will 
not have cancer
993 988 979 968
Women that will 
have cancer
7 12 21 32
Unnecessary 
biopsies
43 37 35 30
False-positive 
results
294 294 256 219
Overdiagnosis 3 3 No reliable data No reliable data
Deaths prevented 
by screening
<1 1 1 2
Number needed to 
screen to prevent 
one cancer-related 
death
1724 1333 1087 645
Table 1. 
Benefits and harms of mammographic breast cancer screening [4].
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2. Recommendations to breast cancer screening around the world
The U.S. Preventive Services Task Force (USPSTF) is an independent volunteer 
panel of American experts that develops recommendations regarding the efficacy 
of preventive services to asymptomatic patients. These recommendations are based 
on both benefits and harms that programs might cause, without consideration to 
the cost of the intervention. Current data about mammographic screening are solid 
regarding the benefits of this strategy when used in women over 50 years old and 
the USPSTF recommends a mammogram every two years, in women between 50 
and 74; however, this same agency does not consider that there is enough evidence 
to support mammographic screening from 40 to 49 years old in asymptomatic 
patients without increased risk to breast cancer [12]. This recommendation is due 
to the fact that screening in this age range results in a smaller number of prevented 
deaths when compared to more advanced ages; also leads to a larger number of 
unnecessary biopsies; and to the possibility of psychological problems, like anxiety, 
because of the large number of false-positive results. While mammographic  
screening of 10,000 asymptomatic women between 50 and 59 years old can prevent 
8 breast cancer deaths, the same strategy adopted in asymptomatic women between 
40 and 49 years old would prevent only 3 breast cancer deaths [13, 14]. Another 
harm associated with mammographic screening of an asymptomatic population 
considered by the USPSTF when issuing their recommendation is the occurrence 
of over diagnosis. Although it is extremely complex to calculate the proportion of 
diagnosed cases that would never evolve to cancer, the best estimates from random-
ized clinical trials suggest the occurrence of over diagnosis in 20% of the cases due 
to mammographic screening [15].
Another agency that carefully evaluated the cost–benefit ratio of mammographic 
screening in asymptomatic women between 40 and 49 years old was the Ontario 
Health Technology Advisory Committee through a systematic review of the literature 
[16]. This work included an evaluation of the USPSTF report [17], the Canadian 
Preventive Services Task Force (CPSTF) report [18], a Cochrane systematic review 
[19], five health technology assessments and eight randomized clinical trials [20–27] 
with the objective to assess the reduction of the breast cancer mortality in this age range 
attributable to mammographic screening. This agency reached a similar conclusion 
as the USPSTF that the mammographic screening in an asymptomatic population 
between 40 and 49 years old is not effective in reducing breast cancer mortality and 
that the harms associated with this intervention, like exposure to radiation, high rate 
of false-negatives leading to delays in diagnosis and high rate of false-positives with 
associated psychological harmful effects should not be overlooked.
The Brazilian College of Radiology (BCR) and Brazilian Society of Mastology 
(BSM) however issued a different recommendation, based on different published 
articles of international literature and methodologically inferior to the ones evalu-
ated and with a clear selection bias [25, 28, 29]. In these studies, it was demon-
strated a breast cancer mortality reduction between 18% and 38% in the studied 
populations. The main point to justify the recommendation of mammographic 
screening for asymptomatic women between 40 and 49 years old is to emphasize 
that in this developing country there is a higher proportion of breast cancer patients 
in this age range when compared to developed countries [30]. Despite the fact that 
it is a recommendation for Brazil, it did not include a single Brazilian study in the 
analysis. This scenario is repeated throughout Latin America as it has been shown 
in a report by The Economist Intelligence unit. Cancer care registries are lacking 
in Latin America due to insufficient coverage of the population and also due to low 
quality [31]. Without local high-quality data, it is impossible to perform local health 
technology assessments and the decision-making process is jeopardized.
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3. Ethical implications of mammographic screening
Carefully considering the recommendations of these three different countries 
with very diverse populations, we can conclude that although mammographic 
screening in women between 40 and 49 provide a modest benefit in reducing breast 
cancer mortality, the occurrence of adverse effects is more pronounced.
We can also note that the BCR and BSM adopt a paternalistic approach, 
reflecting the principle of beneficence. In the meantime, the USPSTF and the 
CPSTF advocate that the screening decision should be shared with the patient. 
This way, patients that are more risk averse could opt out of the screening pro-
gram and patients that value more the potential benefits could opt in, following 
the principles of non-maleficence and autonomy. However, what we must ask is 
whether it is possible to convey important information regarding the risks associ-
ated with a screening program in a clear and, more important, neutral manner. 
In this sense, it is of utmost importance that the autonomy principle is respected 
and that patients are not manipulated to undergo tests or treatments which they 
do not agree with, due to the use of biased information.
Addressing this issue, Biddle introduced the concept of epistemic risk, defined 
as the risk of error that comes up at any moment in the process of knowledge pro-
duction [32]. These errors can happen because of biases during the data collection 
step and also because of decisions made in scenarios of uncertainty. These decisions 
reflect the set of values of the involved researchers and have consequences to human 
health and to the definition of public policies. Rudner agrees with this argument 
and suggests that it’s impossible to prove any hypothesis with full certainty, as there 
is always a possibility of error. This way, researchers must judge what is the neces-
sary amount of data to accept or reject a hypothesis and this judgment depends 
on the set of values of the researcher and on the importance of the consequences 
an error can lead to [33]. Pramesh et al. discuss such a conflict in depth when they 
justify the necessity of a randomized clinical trial to prove a hypothesis raised by a 
cross-sectional study, as they believe the data gathered in the latter is not sufficient 
to support the decision-making process [34].
The reasoning to support a mammographic screening program for asymptomatic 
women below the age of 50 is not free of the risk of epistemic risks. One kind of 
epistemic risk associated with to mammographic screening is the inductive risk, 
defined as the risk of incorrectly accept or reject a hypothesis based on the available 
evidence [35]. Breast surgeons must accept or reject that a patient has a disease, 
frequently a ductal carcinoma in situ (DCIS), that will evolve causing symptoms 
and death based on evidence that does not guarantee the veracity of this hypothesis. 
That happens mostly because of the lack of evidence to predict which cases of DCIS 
will evolve to become invasive carcinomas. Another epistemic risk, the one in the 
gathering of data of breast biopsies, occurs in the evaluation of the differential 
diagnosis between atypical hyperplasia and DCIS. While the first ones are treated 
with a small surgical procedure, the latter requires surgical excision followed by 
radiation therapy and, in some cases, endocrine therapy for 5 years. This way, 
an error committed by the pathologist might lead to an enormous impact in the 
treatment of the patients. As pathologists have different formations and differ-
ent experience backgrounds, and as the biopsy evaluation is a subjective process, 
this is an epistemic risk that is hard to be assessed. In order to try and decrease the 
odds of such an error is the development of image analyses software. Mercan et al. 
evaluated 240 breast biopsies comparing the performance of three experienced 
pathologists and an automated image analysis method. In this study, the auto-
mated method performed better than the pathologists in differentiating atypical 
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hyperplasia and DCIS, becoming a promising alternative for the near future [36]. 
As we saw in these two examples, the information conveyed to the patients eligible 
to screening are not obtained in the absence of the researchers personal judgment 
and values. Thus, more than just respecting the autonomy principle in the shared 
decision-making process, healthcare workers must convey not only the necessary 
information but also their values and personal beliefs used by them to define their 
diagnostic and therapeutic decisions. As long as there is ambiguity in the results 
of mammographic screening studies in asymptomatic women below the age of 50, 
the priority should be debating the advantages and disadvantages of this strategy, 
instead of discrediting their opponents [37].
4. Current situation of mammographic screening
In Brazil, as in many developing countries, there is no public policy to the 
implementation of an organized mammographic screening program. As mentioned 
previously, there is a recommendation from the Brazilian National Cancer Institute 
(INCA) for mammogram every two years for women between 50 and 69 years old 
[7] and the main medical societies recommend an annual mammogram for women 
starting at 40 years of age [30].
This difference in recommendations happens due to complex interactions 
between the country’s decision makers’ interests, beliefs, perspectives and personal 
values. In the present scenario, with this disparity of recommendations, patients 
present late stage diagnosis, worse than the ones observed in Norway before the 
implementation of the local mammographic screening program (Table 2) [38].
To evaluate the necessity to expand the INCA’s recommendation to other age 
ranges, Brito et al. analyzed all breast cancer cases, all DCIS cases and all breast 
cancer related deaths in the city of Aracaju between 1998 and 2014, dividing pages 
according to age groups [39]. The breast cancer incidence trends remained stable 
over the studied period across all age groups. Both incidence and cancer-specific 
mortality in that municipality were similar to the ones observed in countries with 
the same human development index. The authors concluded that, as these rates 
remained stable in all age groups, including the ones in which screening is recom-
mended, the investment of public resources to screen women below the age of 50 or 
over the age of 69 is not justifiable.
A broader study by Rodrigues et al. evaluated retrospective data regarding 
mammograms between 2008 and 2016 in the public health system [40]. Around 
nineteen million mammograms were performed in this period with an increase 
in coverage of 14.5% annually between 2008 and 2012 followed by a stable period 
Stage Brazil (n = 22,527) Norway (n = 26,883)
I 21.3% 48.5%
II 35.2% 38.5%
III 25.2% 5.3%
IV 8.9% 6.5%
Unknown 1.6% —
Adapted from Tiezzi et al. [38].
Table 2. 
Prevalence of breast cancer according to stage in the state of São Paulo between 2000 and 2017, and in Norway 
before the implementation of mammographic screening.
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between 2012 and 2017. The population coverage of mammogram varied in the 
period from 14.4% to 24.2% of the target population. This number is far from the 
70% coverage recommended by the WHO, necessary to effectively reduce breast 
cancer-specific mortality [41]. Rodrigues et al. also evaluated the number of mam-
mogram machines available in the country, their geographical distribution and the 
total number of exams performed in 2016 [42]. In this study, it was demonstrated 
that Brazil has 4628 machines with a capacity of 14,279,654 exams per year. In 
2016, however, only 4,073,079 exams were performed, 29% of the total capacity, 
displaying a clear under-use of the available infrastructure. The low coverage of 
the target population with the stable trend in the past few years associated with the 
under-use of the available infrastructure raises the hypothesis of the existence of 
barriers to access to the healthcare system.
The Barretos Cancer Hospital adopted an alternative to improve the coverage 
of the screening program with the use of mobile mammogram machines in trucks 
reaching 108 municipalities in the northeastern region of São Paulo, targeting 
women between 40 and 69 years old. Greenwald et al. evaluated the efficacy of this 
initiative from 2010 to 2015 [43] and, in this period, 122,634 women were evalu-
ated with a coverage of 54.8% of the target population, referral of 12.25% of these 
women were referred for additional exams with a cancer detection rate of 3,63/1000 
women. 92.51% of the referrals to treatment centers were successfully accepted. The 
results obtained by this program are very promising, showing the potential to be 
expanded to other regions and other countries.
5. Barriers to access the healthcare system
Brazil is a developing country with a population of 209.3 million inhabitants 
with enormous social and economical disparities between its 5 regions [44]. 
Moreover, there are also inequalities in the distribution of human resources and 
health infrastructure with a significant variation in the number of hospital beds 
and physicians dedicated to oncological patients leading to significant differences 
in health outcomes [8]. Another source of outcome variability is the duality of 
access to the healthcare system. Every Brazilian citizen has unrestricted access to 
the public health system (PHS) and the richer portion of the population also has 
access to private healthcare providers through out-of-pocket direct expending or 
through healthcare insurance companies. This duality of the system is perverse in a 
way that it perpetuates the idea that a small portion of the population has access to 
state-of-the-art diagnostic and treatment facilities while the majority of the popula-
tion, around 71%, depends exclusively on the PHS with all its limitations. When 
comparing this two scenarios, we observe a striking difference in the initial stage 
of the breast cancer patients; the majority of the patients seen in the private setting 
is diagnosed with early stage tumors, whereas the majority of patients that depend 
on the PHS is diagnosed with locally advanced tumors [45], a clear indication that 
difficulties to access the healthcare system are the main obstacles to early detection. 
37% of the breast cancer cases diagnosed in the PHS are stage III or IV while in 
the private sector this number falls to 16.2% [46]. These data are corroborated by 
national studies that showed intervals of 75 to 185 days between initial symptom 
presentation and initial biopsy [45] and a median interval of 113.4 days between 
indication and initiation of radiation therapy [47]. For comparison purposes, 
patients seen in the private setting can have diagnostic tests and start treatment in 
less than 30 days.
To identify the main barriers to access to the PHS, Vieira et al. conducted a 
systematic review of the literature identifying 30 publications on this topic [48].  
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In a general analysis, it has been identified an underuse of mammogram machines 
on the north and northeast regions of the country and a mammogram coverage of 
only 35% of the Brazilian women, most of them in the private setting. The main 
issues related with not having a mammogram performed are non-white ethnic-
ity, low educational level, low familiar income and not having health insurance. 
Another interesting finding of this study is that normally the treatment of breast 
cancer is performed in big cities and patients end up traveling more than 100 miles 
from their residences to the hospitals [49]. Even before the start of treatment, 
patients have to face delays of more than 60 days in 36.9% of the cases, because of 
inefficient referral and navigation. The main issues related with delays in the initia-
tion of treatment were non-white ethnicity, not having a partner, low educational 
level, early stage breast cancer and dependence of the PHS [50]. Exclusive depen-
dence on the PHS and non-white ethnicity were also associated with higher breast 
cancer-specific mortality [51].
6. Recommendation and discussion of the ethical dilemma
Considering the inefficacy of the screening programs in developing countries 
and the lack of solid evidence supporting screening of asymptomatic women below 
the age of 50 years old, we recommend resources reallocation to improve access to 
the healthcare system and the implementation of a fast track between diagnostic and 
treatment facilities to symptomatic patients, based on the hierarchical flow proposed 
by Migowski et al. (Figure 1) [52]. This algorithm proposes three different actions: 
educational activities in primary care facilities to raise awareness regarding breast 
cancer and also the potential benefits and harms of mammographic screening; to 
offer the option of screening mammogram to asymptomatic women aged 50 to 69 
during their visit to the primary healthcare provider; and to promote priority access 
to symptomatic patients, without the need of prior scheduling, in which the ones 
with suspicious lesions will be referred to diagnostic facilities. This recommenda-
tion is supported by Rawls’ two principles of justice [9]. The first principle governs 
that all persons have equal rights and freedoms. The second principle governs 
that the adoption of policies that generate social or economical inequalities is only 
acceptable if it favors the least advantaged portion of society. The promotion of 
educational activities proposed by Migowski et al. [52] is supported by Rawls’ first 
principle since it standardizes the access to a basic right, education. The second part 
of the recommendation is justified by Rawls’ second principle of justice. The adop-
tion of a fast track to symptomatic patients, removing the need of a prior appoint-
ment or referral, promotes the reallocation of public resources to remove barriers 
in the access to care, reducing delays in diagnosis and treatment and, therefore, 
reducing inequalities in favor of the least advantaged part of the population that 
relies solely in the public health system. Although the recommendation favors a part 
of the population, it does not violate individual rights, as asymptomatic patients 
will still have access to screening mammogram in their routine visits to their 
primary healthcare providers. Moreover, the proposed recommendation promotes 
equal access to breast cancer diagnosis and treatment as it removes the age bound-
aries, starting to provide care to women below the age of 50 years old, an age range 
responsible for a large amount of new cases in developing countries and that were 
not previously included in the past recommendation [6].
Let us consider for a moment a hypothetical scenario in which the healthcare 
system works perfectly without any access barriers. Even in this setting, mam-
mographic screening as it is currently suggested would not be ideal in developing 
countries. The current evidence that recommends mammographic screening is not 
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unanimous and large randomized clinical trials did not show a robust mortality  
reduction attributable to it [13, 53]. Moreover, even if these studies showed a 
significant mortality reduction attributable to screening mammogram, their results 
would hardly be applicable to the developing countries’ realities. Those studies 
were conducted in countries with high human development index (HDI) and in the 
context of organized screening. Brazil and most developing countries have lower 
HDIs and promote opportunistic screening due to the weak organizational struc-
ture of the healthcare system. This way, the international studies that assessed the 
effectiveness of mammographic screening lack the necessary external validity to be 
applied in developing countries. A recent article published by Vale et al. suggested, 
that the opportunistic screening program employed in the state of São Paulo, Brazil, 
promoted an increase in early stage diagnosis without, however, presenting data 
regarding mortality reduction [54]. Without data showing mortality reduction 
attributable to the screening program it is impossible to conclude whether this model 
is effective or not. Adding up to that data we have some concerning facts associated 
with screening women between the age of 40 and 49; we observe that less than one 
death from breast cancer is avoided for every one thousand screening mammograms 
performed; two hundred and ninety-four false-positive results (Table 1) generate 
additional diagnostic procedures leading to economical impact to the health system 
and also physical and psychological impacts to the patients. Based on everything 
that was exposed in this paragraph, we can conclude is not adequate from Bentham’s 
and Mill’s utilitarianism perspective [10, 11].
In this context, with the shortage of resources to invest in an organized mammo-
graphic screening program and without solid data to justify its implementation, can 
we accept a sub-optimal program? On the one hand, the inexistence of a screening 
program can lead to the increase in the number of cases diagnosed in late stages, for 
which the treatment options might be inaccessible and, sometimes, ineffective. On 
the other hand, developing countries, such as Brazil, sometimes lack the necessary 
infrastructure to perform timely screening mammograms to the whole eligible 
Figure 1. 
Hierarchical flow to promote early diagnosis and treatment of breast cancer. Adapted from Migowski et al. [52].
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population and the consequent breast biopsies of lesions identified through 
screening [55]. In order to consider a screening program adequate, it must be 
acceptable, accessible, and sustainable, it must promote equity and it must be 
economically efficient to the target population [56]. As it has been demonstrated 
in this chapter, the Brazilian mammographic screening program is not accessible, 
since the coverage does not reach 30% of the target population [42]. This program 
is not sustainable either since there is a huge delay between the identification of 
an abnormal mammogram and the necessary biopsy to confirm the diagnostic. 
Due to the incapacity to adequately follow-up and refer patients with abnormal 
findings, the risk of a false-positive result must be considered clinically and 
ethically relevant. Finally, it’s been demonstrated that mammographic screening 
in developing countries is not cost-effective when compared to the alternative 
of treating patients with palpable initial lesions [57, 58]. Contemplating all these 
issues, Sedhom et al. argued that clinical examination of the breast with fast 
referral to avoid delays in diagnosis and treatment, although not a screening 
program, must be considered a more pragmatic and adequate choice than  
screening mammogram in developing countries [59].
7. Conclusion
When weighing the benefits and harms of a mammographic screening program 
in a developing country, in a context where breast cancer-specific mortality has 
been increasing in the past few decades, it is extremely hard to justify increasing 
the age range to women aged 40 to 49 years old from an utilitarian perspective, 
since the amount of resources to establish and make the system work adequately is 
prohibitive. An alternative strategy that promotes easy access and fast referral of 
symptomatic patients, relegating a secondary role to mammographic screening, 
favors a larger and more vulnerable part of the population that depends solely on 
the PHS. This reallocation of resources to favor the least advantaged members of 
society is not only ethically justifiable but also a way of promoting social justice.
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